巨细胞动脉炎的免疫学。

Immunology of Giant Cell Arteritis.

机构信息

Department of Medicine (C.M.W., J.J.G.), Mayo Clinic Alix School of Medicine, Rochester, MN.

Department of Cardiovascular Medicine (C.M.W.), Mayo Clinic Alix School of Medicine, Rochester, MN.

出版信息

Circ Res. 2023 Jan 20;132(2):238-250. doi: 10.1161/CIRCRESAHA.122.322128. Epub 2023 Jan 19.

Abstract

Giant cell arteritis is an autoimmune disease of medium and large arteries, characterized by granulomatous inflammation of the three-layered vessel wall that results in vaso-occlusion, wall dissection, and aneurysm formation. The immunopathogenesis of giant cell arteritis is an accumulative process in which a prolonged asymptomatic period is followed by uncontrolled innate immunity, a breakdown in self-tolerance, the transition of autoimmunity from the periphery into the vessel wall and, eventually, the progressive evolution of vessel wall inflammation. Each of the steps in pathogenesis corresponds to specific immuno-phenotypes that provide mechanistic insights into how the immune system attacks and damages blood vessels. Clinically evident disease begins with inappropriate activation of myeloid cells triggering the release of hepatic acute phase proteins and inducing extravascular manifestations, such as muscle pains and stiffness diagnosed as polymyalgia rheumatica. Loss of self-tolerance in the adaptive immune system is linked to aberrant signaling in the NOTCH pathway, leading to expansion of NOTCH1CD4 T cells and the functional decline of NOTCH4 T regulatory cells (Checkpoint 1). A defect in the endothelial cell barrier of adventitial vasa vasorum networks marks Checkpoint 2; the invasion of monocytes, macrophages and T cells into the arterial wall. Due to the failure of the immuno-inhibitory PD-1 (programmed cell death protein 1)/PD-L1 (programmed cell death ligand 1) pathway, wall-infiltrating immune cells arrive in a permissive tissues microenvironment, where multiple T cell effector lineages thrive, shift toward high glycolytic activity, and support the development of tissue-damaging macrophages, including multinucleated giant cells (Checkpoint 3). Eventually, the vascular lesions are occupied by self-renewing T cells that provide autonomy to the disease process and limit the therapeutic effectiveness of currently used immunosuppressants. The multi-step process deviating protective to pathogenic immunity offers an array of interception points that provide opportunities for the prevention and therapeutic management of this devastating autoimmune disease.

摘要

巨细胞动脉炎是一种中大型动脉的自身免疫性疾病,其特征为三层血管壁的肉芽肿性炎症,导致血管阻塞、血管壁撕裂和动脉瘤形成。巨细胞动脉炎的免疫发病机制是一个累积过程,在这个过程中,一个无症状的长时间潜伏期之后是不受控制的先天免疫,自身免疫耐受的破坏,自身免疫从外周向血管壁的转移,以及最终血管壁炎症的进行性演变。发病机制的每一步都对应于特定的免疫表型,这些表型提供了关于免疫系统如何攻击和损伤血管的机制见解。临床上明显的疾病始于髓样细胞的不适当激活,触发肝脏急性期蛋白的释放,并诱导血管外表现,如肌肉疼痛和僵硬,诊断为巨细胞动脉炎。适应性免疫系统中的自身免疫耐受丧失与 NOTCH 通路中的异常信号有关,导致 NOTCH1CD4 T 细胞的扩增和 NOTCH4 T 调节细胞的功能下降(检查点 1)。外膜血管网络的 adventitial vasa vasorum 内皮细胞屏障缺陷标志着检查点 2;单核细胞、巨噬细胞和 T 细胞侵入动脉壁。由于免疫抑制 PD-1(程序性细胞死亡蛋白 1)/PD-L1(程序性细胞死亡配体 1)通路的缺陷,壁内浸润的免疫细胞到达一个允许组织微环境,其中多个 T 细胞效应谱系蓬勃发展,向高糖酵解活性转变,并支持包括多核巨细胞在内的组织损伤巨噬细胞的发展(检查点 3)。最终,血管病变被自我更新的 T 细胞占据,这些 T 细胞为疾病过程提供自主性,并限制目前使用的免疫抑制剂的治疗效果。从保护性免疫向致病性免疫的多步骤过程提供了一系列的拦截点,为这种破坏性自身免疫性疾病的预防和治疗管理提供了机会。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索